Skip to main content

Table 3 Total mean cost and kaplan-meier estimate per 6-month period (2 years follow-up)

From: Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study

 

First site of relapse

Secondary site

 

Kaplan-Meier estimate (%)

Mean cost (€) [95 CI% (bootstrap)]

Kaplan-Meier estimate (%)

Mean cost (€) [95 CI% (bootstrap)]

0-6 months

78.4%

20 227.39 [15 514.81; 25 342.19]

74.0%

19 141.01 [16 885.80; 21 401.47]

7-12 months

56.6%

18 103.14 [12 747.91; 23 712.83]

52.1%

17 150.03 [14 187.45; 20 139.93]

13-18 months

42.4%

19 173.93 [11 648.09; 27 510.13]

37.1%

14 125.19 [10 996.51; 17 530.20]

19-24 months

36.2%

14 376.70 [7 348.29; 22 564.50]

27.7%

14 774.77 [10 117.74; 20 096.10]